Clovis Oncology (CLVS) IPO Opens Flat
Tweet
Share
E-mailGet Alerts CLVS Hot Sheet
Join SI Premium – FREE
The IPO for Clovis Oncology, Inc. (Nasdaq: CLVS) is open for trading. Shares opened at $13.05 after pricing 10,000,000 shares at $13 per share, the low end of the expected $13-$15 range. The size of the offering was raised from 9,300,000 shares.
J. P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering, and Leerink Swann LLC is acting as co-manager for the offering.
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international market.
J. P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering, and Leerink Swann LLC is acting as co-manager for the offering.
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international market.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aggreko files for proposed IPO
- NorthStrive Acquisition prices $100M IPO on Nasdaq
- Non-Invasive Monitoring Systems files to offer 8.1M shares
Create E-mail Alert Related Categories
IPOsRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
